首页    期刊浏览 2024年12月02日 星期一
登录注册

文章基本信息

  • 标题:Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches
  • 本地全文:下载
  • 作者:Amal Hasan ; Ebaa Al-Ozairi ; Zahraa Al-Baqsumi
  • 期刊名称:ImmunoTargets and Therapy
  • 电子版ISSN:2253-1556
  • 出版年度:2021
  • 卷号:10
  • 页码:63-85
  • DOI:10.2147/ITT.S280706
  • 出版社:Dove Medical Press Ltd
  • 摘要:Coronavirus disease 2019 (Covid-19), caused by the novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can range in severity from asymptomatic to severe/critical disease. SARS-CoV-2 uses angiotensin-converting enzyme 2 to infect cells leading to a strong inflammatory response, which is most profound in patients who progress to severe Covid-19. Recent studies have begun to unravel some of the differences in the innate and adaptive immune response to SARS-CoV-2 in patients with different degrees of disease severity. These studies have attributed the severe form of Covid-19 to a dysfunctional innate immune response, such as a delayed and/or deficient type I interferon response, coupled with an exaggerated and/or a dysfunctional adaptive immunity. Differences in T-cell (including CD4 T-cells, CD8 T-cells, T follicular helper cells, γδ-T-cells, and regulatory T-cells) and B-cell (transitional cells, double-negative 2 cells, antibody-secreting cells) responses have been identified in patients with severe disease compared to mild cases. Moreover, differences in the kinetic/titer of neutralizing antibody responses have been described in severe disease, which may be confounded by antibody-dependent enhancement. Importantly, the presence of preexisting autoantibodies against type I interferon has been described as a major cause of severe/critical disease. Additionally, priorVaccine and multiple vaccine exposure, trained innate immunity, cross-reactive immunity, and serological immune imprinting may all contribute towards disease severity and outcome. Several therapeutic and preventative approaches have been under intense investigations; these include vaccines (three of which have passed Phase 3 clinical trials), therapeutic antibodies, and immunosuppressants. © 2021 Hasan et al.
  • 关键词:SARS-CoV-2;autoantibodies;cytokines;immune regulation;inflammation;neutralizing antibodies;type I interferon
国家哲学社会科学文献中心版权所有